Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9149 |
High Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8808 |
High Similarity |
NPD7819 |
Suspended |
0.8776 |
High Similarity |
NPD2534 |
Approved |
0.8776 |
High Similarity |
NPD2533 |
Approved |
0.8776 |
High Similarity |
NPD2532 |
Approved |
0.8553 |
High Similarity |
NPD7411 |
Suspended |
0.8542 |
High Similarity |
NPD1510 |
Phase 2 |
0.8521 |
High Similarity |
NPD1240 |
Approved |
0.8493 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8456 |
Intermediate Similarity |
NPD6799 |
Approved |
0.8425 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8425 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8403 |
Intermediate Similarity |
NPD1607 |
Approved |
0.8397 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.8387 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.8378 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.8378 |
Intermediate Similarity |
NPD3750 |
Approved |
0.8356 |
Intermediate Similarity |
NPD2796 |
Approved |
0.8323 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8323 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.8313 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.8278 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8258 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8247 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.8247 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.8231 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.8231 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.8217 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8188 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.8187 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.8165 |
Intermediate Similarity |
NPD3749 |
Approved |
0.8153 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.8148 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.8141 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.8125 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.8125 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.8101 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.8092 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8089 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8082 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.8065 |
Intermediate Similarity |
NPD3226 |
Approved |
0.805 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8041 |
Intermediate Similarity |
NPD3748 |
Approved |
0.8039 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7987 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7987 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7971 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7963 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7963 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7943 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7939 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7935 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7925 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7895 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7879 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7866 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7866 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7866 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7831 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7829 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7829 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7826 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7821 |
Intermediate Similarity |
NPD920 |
Approved |
0.7806 |
Intermediate Similarity |
NPD5401 |
Approved |
0.78 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.78 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.78 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7792 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7784 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7784 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7778 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7778 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7755 |
Intermediate Similarity |
NPD411 |
Approved |
0.7751 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.774 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7738 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7738 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.773 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7718 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7697 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7692 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7692 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7692 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7669 |
Intermediate Similarity |
NPD919 |
Approved |
0.7651 |
Intermediate Similarity |
NPD943 |
Approved |
0.7647 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.764 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7635 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7632 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7632 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7622 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7619 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7619 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.76 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.76 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7597 |
Intermediate Similarity |
NPD2654 |
Approved |
0.7595 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7582 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7529 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7516 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7516 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7516 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7516 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7516 |
Intermediate Similarity |
NPD5405 |
Approved |
0.75 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7483 |
Intermediate Similarity |
NPD1019 |
Discontinued |
0.7483 |
Intermediate Similarity |
NPD2798 |
Approved |
0.747 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7468 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7451 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7448 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7413 |
Intermediate Similarity |
NPD5691 |
Approved |
0.74 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7389 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7386 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7381 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7378 |
Intermediate Similarity |
NPD4288 |
Approved |
0.7365 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7362 |
Intermediate Similarity |
NPD37 |
Approved |
0.7361 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7353 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7349 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7341 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7333 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7333 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7329 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7325 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7324 |
Intermediate Similarity |
NPD405 |
Clinical (unspecified phase) |
0.7321 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7315 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7312 |
Intermediate Similarity |
NPD6273 |
Approved |
0.7308 |
Intermediate Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.7299 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7299 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7297 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7297 |
Intermediate Similarity |
NPD1470 |
Approved |
0.7297 |
Intermediate Similarity |
NPD3267 |
Approved |
0.7297 |
Intermediate Similarity |
NPD3266 |
Approved |
0.7296 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7292 |
Intermediate Similarity |
NPD9268 |
Approved |
0.7285 |
Intermediate Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.7284 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7278 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7267 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.726 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.726 |
Intermediate Similarity |
NPD1201 |
Approved |
0.7255 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7255 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7251 |
Intermediate Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.7246 |
Intermediate Similarity |
NPD9266 |
Approved |
0.7246 |
Intermediate Similarity |
NPD74 |
Approved |
0.7244 |
Intermediate Similarity |
NPD1471 |
Phase 3 |
0.7241 |
Intermediate Similarity |
NPD17 |
Approved |
0.723 |
Intermediate Similarity |
NPD1283 |
Approved |
0.723 |
Intermediate Similarity |
NPD3225 |
Approved |
0.7226 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.7219 |
Intermediate Similarity |
NPD6808 |
Phase 2 |
0.7219 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7211 |
Intermediate Similarity |
NPD3972 |
Approved |
0.7192 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7191 |
Intermediate Similarity |
NPD4287 |
Approved |
0.719 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7189 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7184 |
Intermediate Similarity |
NPD3658 |
Clinical (unspecified phase) |
0.7181 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD1164 |
Approved |
0.7176 |
Intermediate Similarity |
NPD5242 |
Approved |
0.7175 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7175 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7174 |
Intermediate Similarity |
NPD9264 |
Approved |
0.7174 |
Intermediate Similarity |
NPD9267 |
Approved |
0.7174 |
Intermediate Similarity |
NPD9263 |
Approved |
0.7174 |
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.717 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7151 |
Intermediate Similarity |
NPD7177 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7134 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7134 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7134 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7134 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.712 |
Intermediate Similarity |
NPD6780 |
Approved |
0.712 |
Intermediate Similarity |
NPD6782 |
Approved |
0.712 |
Intermediate Similarity |
NPD6778 |
Approved |
0.712 |
Intermediate Similarity |
NPD6777 |
Approved |
0.712 |
Intermediate Similarity |
NPD6781 |
Approved |
0.712 |
Intermediate Similarity |
NPD6776 |
Approved |
0.712 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7119 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7117
|
Intermediate Similarity |
NPD1653 |
Approved |